H. Davies, G. Bignell, and C. Cox, Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-54, 2002.
DOI : 10.1006/geno.2000.6354

J. Curtin, J. Fridlyand, and T. Kageshita, Distinct Sets of Genetic Alterations in Melanoma, New England Journal of Medicine, vol.353, issue.20, pp.2135-2182, 2005.
DOI : 10.1056/NEJMoa050092

P. Chapman, A. Hauschild, and C. Robert, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011.
DOI : 10.1056/NEJMoa1103782

A. Hauschild, J. Grob, and L. Demidov, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, pp.358-65, 2012.
DOI : 10.1016/S0140-6736(12)60868-X

G. Mcarthur, P. Chapman, and C. Robert, Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, The Lancet Oncology, vol.15, issue.3, pp.323-355, 2014.
DOI : 10.1016/S1470-2045(14)70012-9

A. Hauschild, J. Grobb, and L. Demidov, An update on overall survival (OS) and follow-on therapies in BREAK, a phase II randomized trial:dabrafenib(D) dacarbazine (DTIC) in patients (PTS) with BRAF V600E, Ann Oncol, vol.25, issue.1, p.1092, 2015.

C. Johannessen, J. Boehm, and S. Kim, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, vol.21, issue.7326, pp.968-72, 2010.
DOI : 10.1038/nature09627

J. Villanueva, A. Vultur, and J. Lee, Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K, Cancer Cell, vol.18, issue.6, pp.683-95, 2010.
DOI : 10.1016/j.ccr.2010.11.023

P. Poulikakos, Y. Persaud, and M. Janakiraman, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, vol.11, issue.7377, pp.387-90, 2011.
DOI : 10.1038/nature10662

H. Shi, W. Hugo, and X. Kong, Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy, Cancer Discovery, vol.4, issue.1, pp.80-93, 2014.
DOI : 10.1158/2159-8290.CD-13-0642

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936420

K. Trunzer, A. Pavlick, and L. Schuchter, Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, issue.14, pp.1767-74, 2013.
DOI : 10.1200/JCO.2012.44.7888

A. Ribas, R. Gonzalez, and A. Pavlick, Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study, The Lancet Oncology, vol.15, issue.9, pp.954-65, 2014.
DOI : 10.1016/S1470-2045(14)70301-8

J. Larkin, P. Ascierto, and B. Dreno, -Mutated Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1867-76, 2014.
DOI : 10.1056/NEJMoa1408868

URL : https://hal.archives-ouvertes.fr/hal-00608409

C. Balch, J. Gershenwald, and S. Soong, Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, pp.6199-206, 2009.
DOI : 10.1200/JCO.2009.23.4799

A. Bucheit, E. Syklawer, and J. Jakob, mutations in patients with metastatic melanoma, Cancer, vol.18, issue.21, pp.3821-3850, 2013.
DOI : 10.1002/cncr.28306

G. Long, D. Stroyakovskiy, and H. Gogas, Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1877-88, 2014.
DOI : 10.1056/NEJMoa1406037

G. Long, D. Stroyakovskiy, and H. Gogas, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, issue.9992, pp.444-51, 2015.
DOI : 10.1016/S0140-6736(15)60898-4

C. Robert, B. Karaszewska, and J. Schachter, Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, pp.30-39, 2015.
DOI : 10.1056/NEJMoa1412690

E. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009.
DOI : 10.1016/j.ejca.2008.10.026

H. Ishibashi, T. Suzuki, and S. Suzuki, Sex Steroid Hormone Receptors in Human Thymoma, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.5, pp.2309-2326, 2003.
DOI : 10.1210/jc.2002-021353

N. Aaronson, S. Ahmedzai, and B. Bergman, The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, JNCI Journal of the National Cancer Institute, vol.85, issue.5, pp.365-76, 1993.
DOI : 10.1093/jnci/85.5.365

P. Ascierto, Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies, Tumori, vol.99, pp.302-307, 2013.

S. Diem, Prognostic score for patients with advanced melanoma treated with ipilimumab, European Journal of Cancer, vol.51, issue.18, pp.2785-91, 2015.
DOI : 10.1016/j.ejca.2015.09.007

C. Robert, B. Karaszewska, and J. Schachter, 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma, European Journal of Cancer, vol.51, p.663, 2015.
DOI : 10.1016/S0959-8049(16)31820-2

S. Kelderman, B. Heemskerk, and T. Van, Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunology, Immunotherapy, vol.369, issue.2, pp.449-58, 2014.
DOI : 10.1007/s00262-014-1528-9

A. Pavlick, A. Ribas, R. Gonzalez, and O. Hamid, Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma, J Clin Oncol, vol.33, issue.9020, 2015.

B. Dreno, A. Ribas, and J. Larkin, Incidence, course, and management of toxicities associated with vemurafenib and cobimetinib in the coBRIM study, Society for Melanoma Research, 2014.

Y. Yan, G. Mcarthur, and T. Gajewski, Vemurafenib and cobimetinib potently inhibit PS6 signaling in BRAFV600 mutation-positive locally advanced or metastatis melanoma from BRIM7 study

C. South-san-francisco and . Usa, 31 Cotellic 20 mg fi lm-coated tablets (summary of product characteristics) Welwyn Garden City, UK: Roche Registration Limited 32 Zelboraf 240 mg fi lm-coated tablets (summary of product characteristics), 2015.